Conventional Chemotherapy and Oncogenic Pathway Targeting in Ovarian Carcinosarcoma Using a Patient-Derived Tumorgraft

@inproceedings{Glaser2015ConventionalCA,
  title={Conventional Chemotherapy and Oncogenic Pathway Targeting in Ovarian Carcinosarcoma Using a Patient-Derived Tumorgraft},
  author={Gretchen Glaser and Saravut John Weroha and Marc A. Becker and Xiaonan Hou and Sergio Enderica-Gonzalez and Sean C. Harrington and Paul J Haluska},
  booktitle={PloS one},
  year={2015}
}
Ovarian carcinosarcoma is a rare subtype of ovarian cancer with poor clinical outcomes. The low incidence of this disease makes accrual to large clinical trials challenging. However, studies have shown that treatment responses in patient-derived xenograft (PDX) models correlate with matched-patient responses in the clinic, supporting their use for preclinical testing of standard and novel therapies. An ovarian carcinosarcoma PDX is presented herein and showed resistance to carboplatin and… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Tumorgrafts as in vivo surrogates for women with ovarian cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2014

KRASmutations in lung cancer

N Karachaliou, C Mayo, +3 authors MA Molina-Vila
Clin Lung Cancer • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…